ACADIA Pharmaceuticals Inc Approval Call Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals DAYBUE FDA Approval Call. My name is Michelle, and I will be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please go ahead.
Thank you. Good morning, and thank you for joining us on today's call to discuss the FDA approval of DAYBUE, trofinetide Oral Solution.
Today's agenda will commence with an introduction from Steve Davis, our Chief Executive Officer, followed by a review of the DAYBUE label and clinical data by Kathie Bishop, our Chief Scientific Officer and Head of rare disease. Then Brent and Tian will discuss our commercialization strategy for DAYBUE. Mark Schneider, our Chief Financial Officer, will provide financial details on our license agreement with Neuren Pharmaceuticals before turning it back to Steve Davis for closing remarks and opening up the call for your questions.
Also on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
